Loading...

The global impact of Precision Medicine Group.
As it happens.

Impact, observations, and insights on the evolving healthcare landscape.

QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)

2023-01-27T17:46:21-05:00News, Press Releases|

QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D) 

QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity

[Frederick, MD – January 24, 2023] Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.   (more…)

PRECISION VALUE & HEALTH NAMES DOUG FULLING PRESIDENT

2023-01-26T09:14:41-05:00News, Press Releases|

Proven Life Sciences Leader Takes Reins to Continue Rapid Growth and
Drive Next-Gen Commercialization Model

BETHESDA, MD (January 26, 2023) Precision Value & Health (PVH), today announces that Doug Fulling has joined as President. As the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, Doug will be accountable for the overall strategy, organizational leadership, financial performance, and next-level growth of this market-leading commercial enterprise.

(more…)

Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics

2022-11-08T19:39:15-05:00News, Press Releases|

BETHESDA, MD — Nov. 3, 2022 — Precision for Medicine, the first biomarker-driven clinical research organization (CRO) supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, announces the culmination of a groundbreaking Next Generation Sequencing (NGS) initiative which improved the accuracy and speed of identifying cancer mutations in solid tumors, allowing researchers and manufacturers to develop patient-specific diagnostics for improved clinical outcomes.

(more…)

Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine

2021-08-05T16:05:51-04:00News, Press Releases|

MALMO, SWEDEN & BETHESDA, MD — August 5, 2021 – Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine.

(more…)

Bigger and Better Together: PRECISIONeffect Acquires Pascāle, Expanding Capabilities with PR and Social Media Services

2021-08-03T08:49:24-04:00News, Press Releases|

Boston – August 3, 2021 – PRECISIONeffect, the industry’s only healthcare advertising agency dedicated to changing the standard of care, today announced that it has acquired Pascāle, an international healthcare communications company specializing in public relations and social media. Pascāle has an almost two-decade history of launching full-scale, creative-fueled PR and social media campaigns to drive results for healthcare clients worldwide.

(more…)

Precision Value & Health Acquires Global Omnichannel Engagement Leader, Across Health

2021-03-23T23:23:57-04:00News, Press Releases|

EU-based team brings a unique omnichannel optimization platform and digital transformation capabilities to leading life-sciences companies

BETHESDA, MDMarch 24, 2021—Precision Value & Health, the industry leader for commercialization services for innovative life science companies, today announced that it has acquired Across Health. Across Health is a leading global omnichannel engagement consultancy focused on providing clients an analytical and evidence-based framework for commercial strategy, execution, and resource optimization. The company’s solutions are based around its proprietary, market-leading Navigator365 product suite, which more than 40 pharmaceutical companies rely on for omnichannel planning and resource allocation. The Across Health team is already working hand-in-hand with Precision’s medical communications, creative, and data sciences teams to offer analytically driven launch and commercialization programs across the product life cycle.

(more…)

Precision Medicine Group Significantly Expands Cell and Gene Therapy Expertise with Acquisition of Project Farma

2021-01-12T15:12:29-05:00Cell & Gene Therapy, Press Releases|

LEADING BIO-ENGINEERING AND MANUFACTURING SERVICES FIRM CATALYZES THE LAUNCH OF PRECISION’S CELL AND GENE THERAPY OFFERING—’PRECISION ADVANCE’—ADDRESSING THE UNIQUE CHALLENGES OF CELL & GENE THERAPY INNOVATORS, FROM DEVELOPMENT THROUGH COMMERCIALIZATION

BETHESDA, MDJanuary 14, 2021—Precision Medicine Group (“PMG”) announced today it has acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies. Project Farma provides Precision a market-leading expertise in the manufacturing of life-changing medicines, with a unique focus in the rapidly growing area of cell and gene therapy. The acquisition adds Project Farma’s unique expertise to Precision’s suite of end-to-end cell and gene therapy capabilities to support development and commercialization.

(more…)

Precision Medicine Group Secures Major Investment from Blackstone

2020-11-20T08:32:56-05:00Press Releases|

New York, NY & Bethesda, MD — November 20, 2020 — Precision Medicine Group (PMG) and Blackstone (NYSE: BX) today announced that PMG, a leading next-generation provider of drug development and commercialization services, has completed a major investment and recapitalization led by funds managed by Blackstone (“Blackstone”). The investment includes significant participation from Precision’s co-founders, Ethan Leder and Mark Clein, as well as current shareholders Berkshire Partners, TPG Growth, Oak HC/FT, and Vida Ventures.

(more…)

Precision for Medicine Partners with Karyopharm Therapeutics to Initiate New Global Clinical Trial to Treat Patients with COVID-19

2020-04-21T17:59:56-04:00Press Releases|

PRECISION FOR MEDICINE PARTNERS WITH KARYOPHARM THERAPEUTICS TO INITIATE NEW GLOBAL CLINICAL TRIAL TO TREAT PATIENTS WITH COVID-19

First Study of an XPO1 Inhibitor to Treat Patients with Severe Viral Infections

Precision for Medicine Responsible for Clinical Trial Management in Europe

BUDAPEST, April 22, 2020 – Precision for Medicine, a pioneer in the design, development and execution of biomarker-informed clinical studies and complex data management, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI) to help conduct the first global randomized clinical trial for low dose selinexor (XPOVIO®), an XPO1 inhibitor, in hospitalized patients with severe COVID-19.

(more…)

Load More Posts